Donald A. Bergstrom, who holds the position of President of Research and Development at Relay Therapeutics, Inc. (NASDAQ: RLAY), completed a substantial equity transaction on June 22, 2026. The executive sold 93,456 shares of the company's common stock, resulting in a total realized value of $1,583,144. This divestment was executed following the exercise of stock options, with the shares traded at a weighted average price of $16.94 per share. Individual transactions within this block occurred at prices ranging from $16.15 to $17.39.
The sale was conducted under the parameters of a Rule 10b5-1 trading plan, a mechanism designed to facilitate pre-arranged stock transactions. Bergstrom originally adopted this specific plan on October 30, 2025. Prior to executing the sale, Bergstrom acquired the identical quantity of 93,456 shares of common stock by exercising stock options at a cost of $4.12 per share, totaling $385,038. These options were governed by a vesting schedule that began on April 2, 2019, with 25% vesting immediately and the remainder distributed in equal quarterly installments over the following thirty-six months. The options carry an expiration date of April 9, 2028. Both the acquisition and subsequent sale were integrated into the established Rule 10b5-1 framework.
Following the completion of these transactions, Donald A. Bergstrom's direct holdings in Relay Therapeutics common stock stand at 418,557 shares. This total position includes 15,037 shares underlying restricted stock units. The executive's transaction activity occurs against a backdrop of recent corporate developments and shifting analyst sentiment. Relay Therapeutics recently announced a $275 million stock offering, which involved pricing 22,916,667 shares at $12 each. This capital raise aims to strengthen the company's financial resources, with provisions for potential additional shares through underwriters.
Market analysts have concurrently adjusted their outlooks on the biotechnology firm. H.C. Wainwright increased its price target to $28, while maintaining a Buy rating, following positive Phase 2 trial results for the drug zovegalisib. Guggenheim raised its price target to $26, citing the drug's promising profile relative to existing treatments. Citizens also boosted its target to $21, highlighting strong trial data with significant response rates. These adjustments reflect optimism from analysts based on recent trial outcomes and expert opinions.